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Abstract Colorectal cancer (CRC) is a multistep process
based on the accumulation of somatic mutations in genes such
as APC and KRAS. Data on the presence of mutations in
KRAS gene in CRC and its relationship with clinicopatholog-
ical parameters and expression of genes involved in tumor
progression are scarce. We unbiasedly examined the KRAS
status in samples from 99 patients and its correlation with
clinicopathological parameters such as age, sex, tumor loca-
tion, lymph node metastasis, tumor stage, tumor grade, and
vascular invasion. Consistent with reports of other re-
searchers, 38.4 % of our samples harbored KRAS mutation
in their genomes with preferential mutation in codon 12
(89.4 %). Nevertheless, unlike previous reports, we were not
able to correlate KRAS status with clinicopathological param-
eters (P>0.05) except for vascular invasion. Patients with
KRAS mutation have more vascular invasion compared with
patient having wild-type KRAS. Next, we investigated the
expression of two tumor suppressor genes, factor-inhibiting
hypoxia-inducible factor 1 (FIH-1) and suppressor of cytokine
signaling (SOCS3), in both KRAS mutant and wild-type
groups and looked for any correlation between their expres-
sion and clinicopathological parameters. Although the expres-
sion of both genes was not regular, none of the clinicopatho-
logical parameters were associated with the expressions of
FIH-1 and SOCS3 at mRNA level (P>0.05). However, de-
cline in FIH-1 expression at protein level in KRAS mutant
group was correlated with stage IV and grade 2 of tumor
(P≤0.05). Our results demonstrated that there is no or low
correlation between KRAS status, FIH-1, and SOCS3 expres-
sion with epidemiologic and clinicpathological characteristics
in CRC.
Keywords Colorectal cancer . KRASmutation . FIH-1 and
SOCS3
Introduction
Colorectal cancer (CRC) is one of the most common cancers
worldwide with an increase in diagnosis of new patients ev-
eryday [1]. CRC is a multistep process based on the accumu-
lation of somatic mutations in genes such as APC and KRAS













1 Department of Molecular Medicine, School of Medicine, Qazvin
University of Medical Sciences, Qazvin, IR, Iran
2 Cellular and Molecular Research Center, Qazvin University of
Medical Sciences, Qazvin, IR, Iran
3 GI and Liver Disease Research Center, Firoozgar Hospital, Iran
University of Medical Sciences, Tehran, Iran
4 Molecular Pathology Department of Mehr General Hospital,
Tehran, Iran
5 Departments of Medical Informatics, School of Allied Medical
Sciences, Tehran University of Medical Sciences, Tehran, Iran
Tumor Biol. (2016) 37:8841–8848
DOI 10.1007/s13277-015-4723-1
associated with resistance to cetuximab, anti-EFGR therapies,
and a lower overall survival [3, 4].
The prevalence of KRAS mutation in CRC patients is 35–
40 %, and the majority of these mutations occur in codon 12
and less frequently in codon 13 of KRAS gene [5, 6]. How-
ever, there are controversial reports on the association between
KRAS mutation and poor CRC outcome. The molecular
mechanisms underlying the correlation between KRAS muta-
tions and CRC are not fully understood.
Hypoxia-inducible transcription factor 1α (HIF-1α) is a
dimeric protein complex which controls angiogenesis, eryth-
ropoiesis, and glycolysis regulation of its target genes under
hypoxic conditions. As HIF-1α activates angiogenesis, it al-
lows cancerous cells to survive and proliferate in low oxygen
conditions and its inhibition provides new clues for HIF-1
targeting in anti-cancer therapy [7]. Factor-inhibiting hypox-
ia-inducible factor 1 (FIH-1) binds to HIF-1 and blocks its
transactivation function [8]. In addition, FIH-1 binds to von
Hippel-Lindau (VHL) tumor suppressor protein, which also
functions as a transcriptional corepressor inhibiting HIF-1α
transactivation [8]. FIH-1 protein is widely expressed in hu-
man tissues, and since FIH-1 is located at chromosome 10q24,
which is often deleted in some cancers, it becomes an impor-
tant candidate gene to study in cancers [9–12].
There are contradictory reports on overexpression or down-
regulation of FIH-1 in cancers [13, 14]. In CRC, it has been
shown that the expression of FIH-1 is significantly declined
[14, 15].
The suppressors of cytokine signaling (SOCS) are inhibi-
tors of cytokine signaling that function through the Janus ki-
nase (JAK)/signal transducers and activators of transcription
(STAT) pathway. Eight SOCS proteins (SOCS-1 to SOCS-7
and CIS) with a similar central SH2 domain and a C-terminal
domain have been identified so far [16]. SOCS proteins, how-
ever, have different mechanisms for negative regulation of
JAK/STAT signaling [17]. Irregularities of the JAK/STAT
pathway are associated with cancer [18]. SOCS3 inhibits
JAK by binding to the cytokine receptor and JAK, recruiting
tyrosine-phosphorylated receptor [19].
The expression of SOCS3 is deregulated in cancers and
plays different roles depending on cancer origin. In head,
neck, hepatocellular, and lung cancers, its expression is down-
regulated by hypermethylation, which causes an enhanced
proliferation [18, 20, 21]. In CRC, the expression of SOCS3
has not yet been evaluated.
To better understand the regulation of FIH-1 and SOCS3
genes in colonic adenocarcinoma specimens, we have exam-
ined the expressions of FIH-1 and SOCS3 in a large charac-
terized series of CRC tissues with and without mutation in
codons 12 and 13 of KRAS gene and investigated their cor-
relation with standard clinicopathological parameters. First,
the frequency of KRAS mutation in 99 CRC samples was
determined, and 38.4 % of patient harbored KRAS mutation,
which was similar to previous reports [5, 6]. In addition, in
agreement with previous reports, most patients with KRAS
mutation had mutation in codon 12 (89.4 %) and a few pa-
tients in codon 13 (10.5 %). There was no significant differ-
ence between KRAS status neither with tumor stage nor its
grade (P>0.05), but it was associated with vascular invasion
(P=0.04).
In contrast with previous reports, expression of neither
FIH-1 nor SOCS3 gene at messenger RNA (mRNA) level
was correlated with clinicopathological parameters. Also, no
correlation was observed between FIH-1 immunohistochem-
istry (IHC) scores and clinicopathological parameters such as
patient age, sex, stage, and vascular invasion (P>0.05). Only
FIH-1 expression was inversely correlated with degree of his-
tological differentiation and tumor grade (P≤0.05). Our re-
sults demonstrated that the expression pattern of FIH-1 or
SOCS3 by itself is not a valid prognostic method in CRC.
Materials and methods
Patient samples
A total of 99 fresh colonic adenocarcinoma tissues were ob-
tained from pathology files of Firuzgar Hospital and Mehr
Hospital (Tehran, Iran) in 2013 with informed written consent
in accordance with Declaration of Helsinki. All tissue samples
were obtained at primary resection. None of the patients had
undergone prior chemotherapy or radiation therapy. All demo-
graphic and clinicopathological data were recorded from cor-
responding pathology reports [age, gender, location of tumor,
tumor grade (well/moderate/poor), depth of invasion, status of
lymph nodes, and liver metastases]. All patients were staged
according to the American Joint Commission for Cancer stag-
ing (AJCC/TNM, the sixth version) system.
DNA extraction
For each case, the percentage of tumor was determined by
reviewing H&E stained slides. DNA was extracted from
formalin-fixed paraffin-embedded (FFPE) specimens using
the QIAamp DNA FFPE Tissue Kit (Qiagen, Germany)
according to the manufacturer’s instructions. The concentrations
were measured using ND-1000 Spectrophotometer (NanoDrop
Thermo Scientific, USA).
KRAS mutation analysis by pyrosequencing
The samples were PCR amplified using the KRAS v2.0 kit
(Qiagen) according to manufacturer’s protocol. Each reaction
contained 1× PCR buffer, 1.5 mmol/l MgCl2, 0.2 mmol/l of
each dNTP, 5 pmol of forward primer, 5 pmol of reverse
primer (biotinylated), 0.8 U of HotStar TaqDNA polymerase
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(Qiagen), 10 ng of template DNA, and dH2O to final volume
of 25 μl. Cycling conditions were as follows: 95 °C 15 min,
38× (95 °C 20 s, 53 °C 30 s, and 72 °C 20 s), 72 °C 5min, 8 °C
hold. Following amplification, 10 μl of biotinylated PCR
product was immobilized on streptavidin-coated sepharose
beads (streptavidin sepharose high performance, GE
Healthcare Bio-Sciences Corp., Piscataway, NJ) and washed
in 70 % EtOH. The purified biotinylated PCR product was
released into the PyroMark Q24 (Biotage, SE) with PyroMark
Gold reagents (Qiagen) containing 0.3-μmol/l sequencing
primer and annealing buffer. The nucleotide dispensation or-
der for codons 12/13 was as follows:
5′ ACGACTCAGATCGTAG-3′ [22].
RNA extraction and complementary (DNA) synthesis
from FFPE specimens
Deparaffinization of microdissected samples was done using
1 ml xylene (Mojalali), was vortexed for 10 s, and centrifuged
in 14,000 rpm for 4 min. The supernatant was discarded; the
pellet was dipped in 1 ml 100 % ethanol (Merck), was
vortexed, and centrifuged as above; and then, the supernatant
was incubated in 37 °C. RNAwas purified by RNeasy FFPE
Kit (50) (Qiagen GmbH) according to the manufacturer’s pro-
tocol. Complementary DNA (cDNA) was synthesized by
High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems) according to the manufacturer’s instructions.
Relative expression levels of HIF-1α and SOCS3
Real-time PCR for genes of interest was carried out using
Light Cycler® Real-Time PCR (Roche Life Science) in a final
volume of 15 μl using Quanti Nova TM SYBR Green PCR
Kit (Qiagen GmbH), 1 μl cDNA (>1 ng) and 0.5 μl (0.2 pmol/
μl) of each primer. Cycling conditions were pre-incubated at
95 °C for 5 min, followed by 40 cycles of 95 °C for 10 s and
63 °C for 30 s. Real-time PCR reactions were run in duplicate.
The threshold cycle (Ct) is defined as the fractional cycle
number at which the fluorescence passes the fixed threshold.
The expression of mRNA targets relative to Hypoxanthine
Phosphoribosyltransferase 1 (HPRT) was determined using
the Livak method. Primer sequences for HIF-1α, SOCS3,
and HPRT are shown in Table 1.
Immunohistochemistry
Immunohistochemistry (IHC) was performed in Pathology
Department of Mehr Hospital. Briefly, 4-mm-thick sections
were prepared from formalin-fixed, paraffin-embedded tissue.
The sections were dewaxed in xylene and were rehydrated in
graduated ethanol solutions. After deparaffinization and rehy-
dration, the sections were retrieved for 10 min with Tris-
EDTA in microwave oven. Endogenous peroxidase activity
was blocked with 10 % hydrogen peroxide (H2O2) for
10 min. The slides were again incubated with primary rabbit
monoclonal (EPR3658) antibody to HIF-1α (ab92498,
RabMAb®) diluted at 1:250 for 60 min at 37 °C. After rinsing
in buffer, the slides were incubated with the secondary anti-
bodies (EnVisionTM + dual-link system-HRP, Dako). Tissue
staining was visualized with a chromogen solution of DAB
substrate (Dako). The slides were counterstained with hema-
toxylin, dehydrated, and mounted. Negative control of
phosphate-buffered solution (PBS) was used as the primary
antibody for the negative controls. Positive control consisted
of samples known to strongly express HIF1AN (human breast
carcinoma).
Scoring criteria
FIH-1α immunohistochemical semiquantitation was per-
formed using the H-score. Five-hundred tumor cells from
the most cellular microscopic high-power fields (×400) were
counted. The H-score is given as the sum of percentage of
stained tumor nuclei multiplied by an ordinal value corre-
sponding to the intensity level (0=none, 1=weak, 2=moder-
ate, and 3= strong). With four intensity levels, the resulting
score ranged from 0 (no staining in the tumor) to 300 (diffuse
intense staining of the tumor).
Table 1 The primers used for real-time PCR reaction











Gly12Ala 5.6 % 5.0 % 5.3 %
Gly12Asp 33.3 % 45.0 % 39.5 %
Gly12Cys 5.6 % 20 % 13.2 %
Gly12Ser 11.1 % 15.0 % 13.2 %
Gly12Val 27.8 % 10.0 % 18.4 %
Gly13Asp 16.7 % 5.0 % 10.5 %
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Statistical analyses
Statistical analyses were performed using SPSS 16.0 software.
The association between non-parametric variables was
assessed with chi-squared test. Parametric variables were
compared using independent sample t test. P<0.05 was con-
sidered to indicate a statistically significant difference. T test
was used to evaluate the difference between HIF-1α and
SOCS3 expression scores between KRAS mutant and wild-
type groups, and chi-squared analysis was performed for cat-
egorical variables. The results were defined as P<0.05 for
statistical significance. Statistical significance was evaluated
with one-way ANOVA with Dunnett’s post hoc test to com-
pare selected groups of data. The ΔΔCt values were used to
determine the statistical significance of differences between
groups for PCR-based studies. Two-way ANOVA with
Bonferroni correction was used to compare selected groups
of data with respect to time. Scatter plot graphs are 2−ΔCt
values for expressed FIH-1α and SOCS3 genes and are nor-
malized against HPRT1 gene.
Results
KRAS mutation
Primary samples from 99 CRC patients were analyzed for
KRAS mutation using pyrosequencing method. From a total
of 99 patients, 61.6 % were KRASwild-type and 38.4 %were
KRAS mutant. It seems that male patients were more likely to
possess KRAS mutation than females (57.8 vs. 42.2 %). Co-
don 12 mutations (89.4 %) were the most common mutation,
whereas codon 13 mutations were less common (n = 4,
10.5 %). The p.G12D point mutation was the most common
mutation of codon 12 (39.5 %), which results in an amino acid
substitution at position 12 in KRAS, from glycine (G) to
aspartic acid (D). On the other hand, p.G12V mutation
(18.4 %) results in an amino acid substitution at position 12
in KRAS, from glycine (G) to valine (V). The p.G12A point
mutation was the least frequently observed point mutation in
codon 12 (Table 2). None of the samples had mutation in
codon 61. The median age of patients was 57 years (27–
93 years); 43 patients (43.3%)were at stage III and 18 patients
(18.2 %) were metastatic at the time of diagnosis. KRAS mu-
tation was found in 44.7 % of stage III tumors, and 55 tumors
(55.6 %) harboring KRAS mutations were well differentiated
(Table 2). Although 57.9 % of mutations were localized in the
right colon, the difference did not reach statistical significance,
most likely due to the limited number of patients (P=0.3).
Patients with KRAS mutations did not exhibit statistically
significant differences in terms of gender, tumor location, tu-
mor grade, presence of lymph node metastasis, stage, and
Table 3 Distributions of clinicopathologic characteristics in KRAS and
wild-type patients with CRC





G1 65.8 % 49.2 %
G2 26.3 % 41 %
G3 7.9 % 9.8 %
Tumor stage 0.89
I 7.9 % 8.2 %
II 26.3 % 32.8 %
III 44.7 % 42.6 %
IV 21.1 % 16.4 %
Tumor localization 0.19
Left colon 12.87 % 28.71 %
Right colon 24.75 % 31.68 %
Vascular invasion 50 % 29.5 % 0.4
Fig. 1 Expression of FIH-1 (a) and SOCS3 (b) in KRAS mutant and wild-type groups and their association with tumor stages
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median tumor diameter. The only difference observed when
comparing KRAS status and vascular invasion in tumors was
that those harboring mutations had more vascular invasion
(P=0.04) (Table 3).
Correlation between FIH-1 and SOCS3 expressions
at mRNA level and clinicopathological parameters
From a total of 99 patients with CRC, 38.4 % had mutation in
KRAS gene and the rest of them had KRAS wild-type gene.
There was no significant difference between KRAS status and
FIH-1 and SOCS3 expressions at mRNA level (P>0.05).
Gene expression analysis was done using real-time PCR
for FIH-1 and SOCS3 genes in both mutant and wild-type
samples. Albeit, the expressions of FIH-1 and SOCS3 showed
deregulation and did not reach statistically significant level
(P>0.05), perhaps due to limited number of samples in stages
I and IV (Fig. 1). In addition, no significant correlation was
found between FIH-1 and SOCS3 expressions at mRNA level
and tumor grades in KRAS mutant and wild-type groups
(P>0.05) (Fig. 2). Also, FIH-1 and SOCS3 expressions were
not significantly associated with vascular invasion and non-
vascular invasion groups in patients with KRAS mutation and
wild-type KRAS (P>0.05) (Fig. 3).
Correlation between FIH-1 expression at protein level
and clinicopathological parameters
FIH-1 was widely expressed among the analyzed colorectal
adenocarcinomas. Ninety-nine percent of tumors stained pos-
itive for FIH-1 in the nucleus compartments (Fig. 4). This
strong nuclear FIH-1 expression was observed in a large pro-
portion of tumor cells, with a median intensity of 2 and a
median percentage of over 80 % of cells. Nearly six percent
of tumors were negative for FIH-1. Nuclear FIH-1 expression
had a 208 median score of cells. Apart from the tumors of
epithelial cells, FIH-1 was widely expressed in non-
epithelial elements within the tumors. FIH-1 was expressed
in stroma of 78 % of tumors, in the vasculature of 81 % of
tumors, and in the infiltrating inflammatory cells in 74 % of
tumors.
As shown in Fig. 5a, the pattern of FIH-1 expression at
protein level and tumor stages have an inverse relationship,
as increase in tumor stage in KRAS mutant group decreases
Fig. 2 Expression of FIH-1 (a) and SOCS3 (b) in KRAS mutant and wild-type groups and their association with tumor grades
Fig. 3 Expression of FIH-1 and SOCS3 inKRASmutant and wild-type groups and their relationship in two groups of patients, having vascular invasion
(a) and not having vascular invasion (b)
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the expression of FIH-1 compared with wild-type group.
However, the correlation of FIH-1 expression and tumor
stages in KRAS mutant and wild-type groups were not statis-
tically significant (P>0.05), except for stage IV in which FIH-
1 is down-regulated in patients with KRAS mutation
(P=0.04).
There was no correlation between the expression of
FIH-1 at protein level and tumor grades in KRAS mu-
tant and wild-type groups (P> 0.05) except for grade 2,
in which the expression of FIH-1 was decreased signif-
icantly in KRAS mutant group compared with wild-type
group (P≤ 0.05) (Fig. 5b). Finally, FIH-1 expression in
both KRAS status in vascular and non-vascular invasion
groups was not statistically correlated (P > 0.05), al-
though it seems to be down-regulated in both groups
in patients with KRAS mutation (Fig. 5c).
Discussion
To better understand the regulation of FIH-1 and SOCS3
genes in colonic adenocarcinoma specimens, we have exam-
ined the expressions of FIH-1 and SOCS3 in a large charac-
terized series of CRC tissues with and without mutation in
codons 12 and 13 of KRAS gene and investigated their cor-
relation with standard clinicopathological parameters.
From a total of 99 patients with CRC, 61.6 % were KRAS
wild-type and 38.4%were KRASmutant. It appears that male
patients are more likely to harbor KRAS mutation than fe-
males (57.8 vs. 42.2 %), which is in contrast with a previous
report [23] perhaps due to differences in number and patient
population. Also, there was no association between KRAS
mutation and tumor stage (P = 0.89) and tumor grade
(P=0.26), which is in contrast with previous reports [23,
Fig. 4 IHC for FIH-1 protein and
strong expression of FIH-1 in
wild-type group (a, b) and weak
expression in mutant group (c, d)
Fig. 5 Expression of FIH-1 expression at protein level in KRAS mutant and wild-type groups using IHC and their correlation with tumor stage (a),
tumor grade (b), and vascular invasion (c)
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24]. However, 57.9 % of mutations were localized in the right
colon but the difference did not reach statistical significance,
most likely due to the limited number of patients (P=0.3).
Moreover, there was no association between KRAS status
and gender, presence of lymph node metastasis, and median
tumor diameter (P>0.05). However, KRAS status was asso-
ciated with vascular invasion. Vascular invasion was seen in
37.4 % of patients, and it happened more frequently in KRAS
mutant group compared with wild-type group (50 vs. 29 %)
(P=0.04).
Detection of a molecular marker such as a unique gene
expression pattern will help us to predict the invasive or mi-
gratory potential of a primary tumor to avoid overtreatment or
undertreatment of patients. So, there are some reports that
show FIH-1 and SOCS3 expressions might be associated with
clinicopathological parameters [7, 10, 14, 21, 25]. Hence, we
analyzed the expressions of FIH-1 and SOCS3 in 99 CRC
cases in search for any correlation between the expression of
both genes and clinicopathological parameters such as tumor
stage, tumor grade, and vascular invasion in KRAS mutant
and wild-type groups. Although the expression of both genes
at mRNA level showed deregulation in KRAS mutant group
compared to wild-type group, it was not correlated to the
tumor stage (P>0.05) (Fig. 1). Perhaps this can be due to
limitation in patient number or the large number of patients
in stage III. In addition, no correlation was found between
FIH-1 and SOCS3 expressions at mRNA level with tumor
grade or vascular invasion (P>0.05) (Figs. 2 and 3). Only at
protein level was the down-regulation of FIH-1 in KRAS mu-
tant group associated with stage IV (P=0.04) and grade II of
tumor (P=0.05).
In summary, first we investigated the frequency of KRAS
mutation in codons 12 and 13 in 99 CRC samples using py-
rosequencing and investigated the correlation between KRAS
status and clinicopathological parameters such as sex, age,
tumor stage, tumor grade, lymph node metastasis, and vascu-
lar invasion. In contrast with previous reports, we did not
observe any correlation between KRAS status and clinico-
pathological parameters (P>0.05) except for vascular inva-
sion. It seems that vascular invasion happened in patients har-
boring KRAS mutation in their genome compared to wild-
type (50 vs. 29%) (P=0.04) [23, 24, 26]. Finally, we analyzed
the expressions of FIH-1 and SOCS3 using qRT-PCR and
correlated the expression results with clinicopathological pa-
rameters. There was no association between the expression of
both genes at mRNA level and clinicopathological parameters
(P>0.05). As described above, decreased expression of FIH-1
at protein level is associated with stage IV and grade II of
tumor level (P≤0.05).
This study suggested that there is no or low correlation
between KRAS status and epidemiologic and clinicopatho-
logical characteristics since in our study, KRAS status was
only correlated with vascular invasion. Furthermore, our
results demonstrated that the prediction of cancer prognosis
using pattern of FIH-1 and SOCS3 expression is not a reliable
approach for prognostic tumor stage, tumor grade, and vascu-
lar invasion. However, more research is needed to evaluate
our results, for example, using large number of CRC samples.
Validation of biomarkers will help to improve management
decisions for individual patients based on tumor biology. No-
tably, this may also be helpful in development of novel ther-
apeutic targets to assist treatment of cancers.
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